Back
Corporate News
Kwality Pharmaceuticals receives CDSCO approval to manufacture Pembroluzimab for preclinical studies
24-Jul-2026, 11:10
Kwality Pharmaceuticals has achieved a significant milestone in its biologics development journey after receiving permission from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies.
Kwality Pharmaceuticals has achieved a significant milestone in its biologics development journey after receiving permission from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies.
The approval follows a comprehensive review of the product's development data submitted by the Company's R&D team. Based on the data evaluated, CDSCO has granted permission to proceed with pilot-scale manufacturing for the generation of preclinical batches, marking the product's transition from the research and development stage to Pre-Clinical stage.